• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索游离脑-血浆药物浓度比的计算机模拟预测:模型验证、更新与解读

Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation.

作者信息

Varadharajan Srinidhi, Winiwarter Susanne, Carlsson Lars, Engkvist Ola, Anantha Ajay, Kogej Thierry, Fridén Markus, Stålring Jonna, Chen Hongming

机构信息

Department of Biology, Lund University, Lund, SE-22100, Sweden; Chemistry Innovation Centre, Discovery Sciences, AstraZeneca R&D Mölndal, Mölndal, SE-43183, Sweden.

出版信息

J Pharm Sci. 2015 Mar;104(3):1197-206. doi: 10.1002/jps.24301. Epub 2014 Dec 24.

DOI:10.1002/jps.24301
PMID:25546343
Abstract

Recently, we built an in silico model to predict the unbound brain-to-plasma concentration ratio (Kp,uu,brain), a measure of the distribution of a compound between the blood plasma and the brain. Here, we validate the previous model with new additional data points expanding the chemical space and use that data also to renew the model. The model building process was similar to our previous approach; however, a new set of descriptors, molecular signatures, was included to facilitate the model interpretation from a structure perspective. The best consensus model shows better predictive power than the previous model (R(2) = 0.6 vs. R(2) = 0.53, when the same 99 compounds were used as test set). The two-class classification accuracy increased from 76% using the previous model to 81%. Furthermore, the atom-summarized gradient based on molecular signature descriptors was proposed as an interesting new approach to interpret the Kp,uu,brain machine learning model and scrutinize structure Kp,uu,brain relationships for investigated compounds.

摘要

最近,我们构建了一个计算机模拟模型,用于预测非结合脑血浓度比(Kp,uu,brain),这是衡量化合物在血浆和脑之间分布情况的一个指标。在此,我们用新增加的数据点验证了先前的模型,这些数据点扩展了化学空间,同时还用这些数据更新了模型。模型构建过程与我们之前的方法类似;不过,纳入了一组新的描述符——分子特征,以便从结构角度促进对模型的解释。最佳共识模型比先前的模型显示出更好的预测能力(当使用相同的99种化合物作为测试集时,R(2) = 0.6,而之前为R(2) = 0.53)。两类分类准确率从使用先前模型时的76%提高到了81%。此外,基于分子特征描述符提出了原子汇总梯度,作为解释Kp,uu,brain机器学习模型并仔细研究所研究化合物的结构与Kp,uu,brain关系的一种有趣的新方法。

相似文献

1
Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation.探索游离脑-血浆药物浓度比的计算机模拟预测:模型验证、更新与解读
J Pharm Sci. 2015 Mar;104(3):1197-206. doi: 10.1002/jps.24301. Epub 2014 Dec 24.
2
Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.整合计算机模拟和体外实验方法以预测药物进入中枢神经系统的可及性
Mol Pharm. 2016 May 2;13(5):1540-50. doi: 10.1021/acs.molpharmaceut.6b00031. Epub 2016 Apr 4.
3
Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model.直接比较利用机器学习方法和机制神经药代动力学模型预测未结合的脑-血浆分配。
AAPS J. 2021 May 18;23(4):72. doi: 10.1208/s12248-021-00604-x.
4
Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems.采用计算和体外模型系统预测中枢神经系统药物研发中脑:血未结合浓度比。
Drug Discov Today. 2018 Jul;23(7):1357-1372. doi: 10.1016/j.drudis.2018.03.002. Epub 2018 Mar 13.
5
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.利用脑间质液和脑脊液中未结合药物浓度的新数据集,研究大鼠和人类的结构-脑暴露关系。
J Med Chem. 2009 Oct 22;52(20):6233-43. doi: 10.1021/jm901036q.
6
In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms.基于机器学习算法的脑-血浆比的无约束比预测的计算机模拟研究。
J Mol Graph Model. 2011 Aug;29(8):985-95. doi: 10.1016/j.jmgm.2011.04.004. Epub 2011 Apr 27.
7
Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay.直接比较总清除率预测:基于计算机器学习模型与基于体外测定的自下而上方法。
Mol Pharm. 2020 Jul 6;17(7):2299-2309. doi: 10.1021/acs.molpharmaceut.9b01294. Epub 2020 Jun 12.
8
Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.用于定量预测脑-血浆和脑脊髓液-血浆未结合浓度比的大鼠、猴子和人类中枢神经系统稳态药物处置模型的转化。
AAPS J. 2021 Jun 3;23(4):81. doi: 10.1208/s12248-021-00609-6.
9
In-silico prediction of blood-brain barrier permeability.计算机预测血脑屏障通透性。
SAR QSAR Environ Res. 2013 Jan;24(1):61-74. doi: 10.1080/1062936X.2012.729224. Epub 2012 Oct 24.
10
Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.卡马西平及其九种衍生物的药代动力学、脑分布和血浆蛋白结合:用于预测性计算 ADME 模型的新数据集。
Epilepsy Res. 2013 Nov;107(1-2):37-50. doi: 10.1016/j.eplepsyres.2013.08.013. Epub 2013 Sep 3.

引用本文的文献

1
The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.卡马替尼的药代动力学及其在非小细胞肺癌治疗中的疗效:一篇叙述性综述。
Transl Lung Cancer Res. 2025 Jul 31;14(7):2842-2852. doi: 10.21037/tlcr-2025-700. Epub 2025 Jul 28.
2
Prediction of the Extent of Blood-Brain Barrier Transport Using Machine Learning and Integration into the LeiCNS-PK3.0 Model.使用机器学习预测血脑屏障转运程度并将其整合到LeiCNS-PK3.0模型中。
Pharm Res. 2025 Feb;42(2):281-289. doi: 10.1007/s11095-025-03828-0. Epub 2025 Feb 10.
3
Preclinical evaluation of targeted therapies for central nervous system metastases.
中枢神经系统转移的靶向治疗的临床前评估。
Dis Model Mech. 2024 Sep 1;17(9). doi: 10.1242/dmm.050836. Epub 2024 Sep 30.
4
KRAS Inhibitors in Non-Small Cell Lung Cancer: A Review.非小细胞肺癌中的KRAS抑制剂:综述
Onco Targets Ther. 2024 Aug 24;17:683-695. doi: 10.2147/OTT.S473368. eCollection 2024.
5
Predicting blood-brain barrier permeability of molecules with a large language model and machine learning.利用大语言模型和机器学习预测分子的血脑屏障通透性。
Sci Rep. 2024 Jul 9;14(1):15844. doi: 10.1038/s41598-024-66897-y.
6
Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.评估小分子进入中枢神经系统的实验和计算方法。
Molecules. 2024 Mar 13;29(6):1264. doi: 10.3390/molecules29061264.
7
Accurate prediction of K based on experimental measurement of K and computed physicochemical properties of candidate compounds in CNS drug discovery.在中枢神经系统药物发现中,基于对K的实验测量以及候选化合物计算得到的物理化学性质对K进行准确预测。
Heliyon. 2024 Jan 9;10(2):e24304. doi: 10.1016/j.heliyon.2024.e24304. eCollection 2024 Jan 30.
8
The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery.从药物发现中ADME评价角度看计算机模拟模型的趋势与未来展望
Pharmaceutics. 2023 Nov 12;15(11):2619. doi: 10.3390/pharmaceutics15112619.
9
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.威帕他尼是一种药理先进的 RET 选择性抑制剂,具有较高的中枢神经系统穿透性和对 RET 溶剂前沿突变的抑制活性。
Nat Cancer. 2023 Sep;4(9):1345-1361. doi: 10.1038/s43018-023-00630-y. Epub 2023 Sep 21.
10
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer.驱动基因阳性的非小细胞肺癌颅内转移的新兴治疗方法和评估标准的演变。
Nat Rev Clin Oncol. 2023 Oct;20(10):716-732. doi: 10.1038/s41571-023-00808-4. Epub 2023 Aug 17.